Advances in Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer - PubMed
3 hours ago
- #BCG
- #Intravesical Therapy
- #NMIBC
- Non-muscle-invasive bladder cancer (NMIBC) accounts for 75% of newly diagnosed bladder cancer cases.
- Intravesical therapy is the cornerstone of NMIBC management post-TURBT.
- Low-risk NMIBC benefits from immediate single instillation of chemotherapy after TURBT.
- Intermediate-risk patients may benefit from intravesical chemotherapy or BCG, with emerging therapies like UGN-102 showing promise.
- High/very high-risk NMIBC standard care is full-dose, 3-year BCG instillation, though shortages and failures necessitate alternatives.
- Optimized BCG regimens, like two induction courses, aim to preserve efficacy and improve feasibility.
- Sequential gemcitabine and docetaxel instillation shows favorable outcomes in BCG-naïve and BCG-unresponsive patients.
- Novel therapies under investigation for BCG failure include gene therapy, oncolytic viral therapy, interleukin-15 superagonist, and innovative drug delivery systems.